This alternative metabolic pathway ensures the production of MUFAs when SCD is inhibited, thereby offering the strategy of combined inhibition of both FADS2 and SCD to reduce hepatocellular carcinoma.43 The gene discussed is SCD; the disease is hepatocellular carcinoma.